Clinical trials: Stem Cell
Type 2 Diabetes
Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus
Umbilical cord mesenchymal stem cells (SC) transplantation was a novel therapy for diabetes mellitus, with less side effects and more advantages.
- Trial name
- NCT01954147
- Testing
- GLP-1, SC, Standard Medical Treatment
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Diabetes Care Center of Nanjing Military Command
Sickle Cell Disease, Beta Thalassemia
Stem Cell Transplant in Sickle Cell Disease and Thalassemia
The primary purpose of this study is to see if giving lower doses of chemotherapy (moderately ablative) will result in successful bone marrow replacement without as severe side-effects but with permanent control of the disease.
- Trial name
- NCT00408447
- Testing
- Busulfan, Fludarabine, Alemtuzumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Columbia University
Retinal Degeneration, Retinitis Pigmentosa
Stem Cells Therapy in Degenerative Diseases of the Retina
The purpose of this study is to test the safety and effectiveness of an autologous bone marrow-derived stem/progenitor cells administered intravitreously in the subjects with degenerative diseases of the retina.
- Conditions
- Retinal Degeneration, Retinitis Pigmentosa, Age Related Macular Degeneration, Stargardt Disease 1
- Trial name
- NCT03772938
- Testing
- Stem/progenitor cells transplantation
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- Pomeranian Medical University Szczecin
Immune Effector Cell Associated Hematotoxicity
Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in the Treatment of Long-Term Cytopenia After CAR-T Therapy
This study is a single arm, open label, exploratory clinical study aimed at evaluating the efficacy, and safety of allogeneic umbilical cord blood-derived mesenchymal stem cells in the treatment of long-term cytopenia after CAR-T…
- Trial name
- MSC-ICAHT (NCT07212335)
- Testing
- Mesenchymal Stem Cell Infusion
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Graft-versus-host Disease
MSC for Treatment of cGVHD After Allo-HSCT
The purpose of this study is to evaluate the efficacy of mesenchymal stem cells in patients with chronic graft-versus-host disease.
- Trial name
- NCT04692376
- Testing
- Mesenchymal stem cells, Glucocorticoids, cyclosporine
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Heart Attack, NSTEMI
A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction
This is a double-blind, sham-controlled clinical study to evaluate the safety and feasibility of AMI MultiStem therapy in subjects who have had a heart attack (Non-ST elevation MI).
- Trial name
- MI-NSTEMI (NCT02277613)
- Testing
- AMI MultiStem cells
- Where
- 11 sites in United States
- Volunteers
- 34 people
- Sponsor
- Healios K.K.
Parkinson Disease
Phase 1/2a Study of ANPD001 in Parkinson Disease
This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease.
- Trial name
- ASPIRO (NCT06344026)
- Testing
- ANPD001, Custom Device
- Where
- 9 sites in United States
- Volunteers
- 9 people
- Sponsor
- Aspen Neuroscience
Pediatric Cancer
Granulocyte Transfusions After Umbilical Cord Blood Transplant
Although most children with leukaemia are cured using drugs (chemotherapy) alone, for some children additional treatments are needed. Stem cell transplant can cure children where chemotherapy and other drugs have failed.
- Trial name
- NCT05425043
- Testing
- Granulocytes
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Manchester
Graft Versus Host Disease, Leukemia
Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and melphalan, before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Myeloma
- Trial name
- ProT4 (NCT01240525)
- Testing
- CD4 DLI, No DLI
- Where
- 11 sites in United Kingdom
- Volunteers
- 114 people
- Sponsor
- University College, London
MDS
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk
Comparison of survival in patients with or without a matched donor at 36 months
- Trial name
- NCT02757989
- Testing
- transplantation
- Where
- 37 sites in France
- Volunteers
- 79 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Infection
Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation
RATIONALE: Antivirals such as valganciclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valganciclovir is effective in preventing cytomegalovirus.
- Trial name
- NCT00016068
- Testing
- ganciclovir, valganciclovir
- Where
- 7 sites in United States
- Volunteers
- 184 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma, High-Grade
R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS)
Purpose: to evaluate an efficacy of chemotherapy regimens R-DA-EPOCH-21 and R-BL-04 with and without autologous hematopoietic stem cells transplantation (auto-SCT) in newly diagnosed patients with High-Grade B-cell Lymphoma…
- Trial name
- NCT03479918
- Testing
- R-DA-EPOCH-21, R-BL-M-04, R-DA-EPOCH-21 + auto-SCT
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- Elena N.Parovichnikova
Menin Inhibitors, Post Hematopoietic Stem Cell Transplantation
Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia
This is a phase 2, open label, single arm trial. This study aims to assess the efficacy and safety of menin inhibitor BN104 as maintenance therapy in patients with acute leukemia harboring specific genetic alterations who have…
- Conditions
- Menin Inhibitors, Post Hematopoietic Stem Cell Transplantation, Maintenance Therapy, Acute Leukemia
- Trial name
- NCT07101497
- Testing
- BN104 monotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia, Lymphoma
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia
RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00002718
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hodgkin Lymphoma, Lymphocytic Leukemia
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
Background: Allogeneic blood and marrow stem cell transplantation (BMT) plays an important role in the curative treatment of a number of pediatric malignancies.
- Conditions
- Hodgkin Lymphoma, Lymphocytic Leukemia, Mixed Cell Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00013533
- Testing
- Stem cell transplantation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Hematologic Malignancy
Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation
The LLLT has an anti-inflammatory, analgesic effect and accelerates the healing of ulcerated lesions. There are little data in the literature showing its efficacy in prevention of mucositis in cohorts of patients with…
- Trial name
- STOP MUCITES (NCT02696408)
- Testing
- Laser treatment
- Where
- 3 sites in France
- Volunteers
- 234 people
- Sponsor
- Institut de Cancérologie de la Loire
Blood Cancer, Blood and Marrow Transplant (BMT)
Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors
To evaluate the use of unrelated donors for hematopoietic cell transplantation in the treatment of hematologic and lymphoid malignancies.
- Trial name
- NCT00186225
- Testing
- ablative allogeneic hematopoietic cell transplantation
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Stanford University
Lymphoproliferative Disorders
Transfusion-related EBV Infection Among Allogeneic Stem Cell Transplant Pediatric Recipients
In many countries, numerous steps are taken to minimize the risk of infection from transfused blood products. Typically, blood banking organisations will screen for an array of infectious pathogens as part of their quality…
- Trial name
- TREASuRE (NCT02505789)
- Testing
- Determining the source of EBV in severe EBV infections
- Where
- 3 sites in Canada
- Volunteers
- 324 people
- Sponsor
- St. Justine's Hospital
Neuroblastoma
Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma
RATIONALE: Giving chemotherapy before an autologous stem cell transplant stops the growth of tumor cells by stopping them from dividing or by killing them. It also prepares the patient's bone marrow for the stem cell transplant.
- Trial name
- NCT00526318
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- 68 sites in Germany, Switzerland
- Volunteers
- 360 people
- Sponsor
- German Society for Pediatric Oncology and Hematology GPOH gGmbH
Haematological Malignancy
Kinectics of Donor-specific Anti-HLA Antibody After HLA-incompatible Allogeneic Haematopoietic Stem Cell Transplantation
Donor specific anti-HLA antibody (DSA) is closely related not only to primary graft rejection (GR) after HLA-incompatible transplantation, but also to the occurrence of primary PGF.
- Trial name
- NCT06395220
- Testing
- Detection of donor-specific anti-HLA antibody (DSA)
- Where
- China
- Volunteers
- 314 people
- Sponsor
- Peking University People's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.